Opinion|Videos|October 28, 2024
Treatment Considerations for PSMA-Positive mCRPC Patients
Author(s)Neal Shore, MD, FACS
Neal Shore, MD, FACS, highlights the exciting advancements in radioligand therapy for prostate cancer, noting that ongoing trials are exploring its use in various disease stages and settings, and emphasizes the importance of reviewing the VISION and FORE trial publications for further insights.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on Urology Times
1
Alternative BCG strains may help address ongoing supply challenges in NMIBC
2
Doublet or triplet? Urologists weighs in on mCSPC options
3
Pearls & Perspectives: Sexual Health and Intimacy in Midlife, With Karen Bigman, MBA
4
The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH
5